Targeting Novel microRNAs in Developing Novel Alzheimer's Disease Treatments

MicroRNA (miRNA) Complexity in Alzheimer’s Disease (AD)

“…RNA-based medications can include stabilized miRNAs, anti-miRNA (AM, antagomir) and other approaches directed against specific miRNA activators such as NF-kB (p50/p65), using targeted anti-NF-kB (p50/p65) treatment strategies, or any combination of these advanced therapeutics. NV, EX and/or EMV packets containing strategically designed and stabilized miRNA, anti-miRNA (AM), mRNA in conjunction with other therapeutic components and inflammatory mediators and tailored to individual AD patients using precision medicine and predictive, participatory, preventive and personalized (P4) approaches should be useful in the clinical management of AD and other complex neurological disorders that are now urgently requiring effective disease-modifying intervention [ 17 , 35 , 53 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 75 , 79 , 80 , 81 , 82 , 100 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 ].…”

“…The intrinsic complexity and magnitude of gene expression in the human brain and CNS make the elucidation of even fundamental miRNA-mRNA signaling pathways exceptionally challenging, as does the search for reliable biomarkers for neurodegeneration in the periphery. The manipulation of gene expression using miRNA-based strategies and the use of extracellular vesicles for therapeutic delivery should be of great strategic value in the clinical management of AD and related forms of progressive age-related inflammatory neurodegeneration [ 31 , 35 , 50 , 51 , 80 , 81 , 82 , 83 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 ].…”

Optimized miR-124 reporters uncover differences in miR-124 expression among neuronal populations in vitro

“…On one hand, because a growing body of evidence suggest that miRNAs dysregulation is a key pathogenic event in multiple diseases ( Liu et al, 2012 ; Gascon et al, 2014 ; Salta and De Strooper, 2017 ). On the other hand, because of their simultaneous action on different biological pathways, they hold a promising potential for therapeutic applications ( Gentile et al, 2022 ; Seyedaghamiri et al, 2023 ).…”

“…On one hand, because a growing body of evidence suggest that miRNAs dysregulation is a key pathogenic event in multiple diseases (Liu et al, 2012;Gascon et al, 2014;Salta and De Strooper, 2017). On the other hand, because of their simultaneous action on different biological pathways, Lepolard et al 10.3389/fnins.2023.1257599 Frontiers in Neuroscience 02 frontiersin.org they hold a promising potential for therapeutic applications (Gentile et al, 2022;Seyedaghamiri et al, 2023). miR-124 is one of the best studied miRNAs because of: (i) its abundance (Lagos-Quintana et al, 2002); (ii) conservation across species and brain enrichment (Lagos-Quintana et al, 2002); (iii) involvement in multiple key biological processes in the brain ranging from neuronal differentiation during development (Makeyev et al, 2007;Maiorano and Mallamaci, 2010) to fine-tuning neurotransmitter receptor composition at the synapse (Hou et al, 2015;Gilbert et al, 2016;Namkung et al, 2023); and (iv) alterations observed in a wide variety of pathological conditions, especially neurodegenerative diseases (Gascon et al, 2014;Wang et al, 2018;Yao et al, 2019;Ghafouri-Fard et al, 2022).…”